Showing results (31-40 of 40) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Molecular Cancer Therapeutics|September 16, 2004
Chemoinducible gene therapy: a strategy to enhance doxorubicin antitumor activityCarlos A Lopez, Eric T Kimchi, Helena J Mauceri, et al.British Journal of Haematology|April 17, 2004
Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myelomaNoopur Raje, Teru Hideshima, Faith E Davies, et al.Cancer Journal (Sudbury, Mass.)|March 16, 2002
Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistanceVinay K Gupta, Nora T Jaskowiak, Michael A Beckett, et al.Cancer Chemotherapy and Pharmacology|November 20, 2002
Angiostatin potentiates cyclophosphamide treatment of metastatic diseaseHelena J Mauceri, Saraswathy Seetharam, Michael A Beckett, et al.Cancer Chemotherapy and Pharmacology|May 12, 2005
Forphenicinol enhances the antitumor effects of cyclophosphamide in a model of squamous cell carcinomaKevin T Murphy, Abdullah Wardak, Michael A Beckett, et al.Molecular Cancer Therapeutics|January 24, 2007
Cell cycle phenotype-based optimization of G2-abrogating peptides yields CBP501 with a unique mechanism of action at the G2 checkpointShi-Ken Sha, Takuji Sato, Hidetaka Kobayashi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremitiesArno J Mundt, Srinivasan Vijayakumar, John Nemunaitis, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2002
Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated dailyJoseph P Eder, Jeffrey G Supko, Jeffrey W Clark, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2011
Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumorsGeoffrey I Shapiro, Raoul Tibes, Michael S Gordon, et al.JCI Insight|October 5, 2016
Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypesPatrick H Lizotte, Elena V Ivanova, Mark M Awad, et al.Pageof 4